JPWO2022177844A5 - - Google Patents

Info

Publication number

JPWO2022177844A5

JPWO2022177844A5 JP2023548874A JP2023548874A JPWO2022177844A5 JP WO2022177844 A5 JPWO2022177844 A5 JP WO2022177844A5 JP 2023548874 A JP2023548874 A JP 2023548874A JP 2023548874 A JP2023548874 A JP 2023548874A JP WO2022177844 A5 JPWO2022177844 A5 JP WO2022177844A5

Authority

JP

Japan

Prior art keywords

gdc

patient

medicament

estrogen receptor

combination

Prior art date

2025-02-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010006187 Breast cancer Diseases 0.000 claims 9
• 206010055113 Breast cancer metastatic Diseases 0.000 claims 9
• 230000035772 mutation Effects 0.000 claims 8
• GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 claims 7
• 229940126088 GDC-9545 Drugs 0.000 claims 7
• 239000003814 drug Substances 0.000 claims 7
• 102000015694 estrogen receptors Human genes 0.000 claims 7
• 108010038795 estrogen receptors Proteins 0.000 claims 7
• 238000000034 method Methods 0.000 claims 7
• SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 claims 6
• 150000003839 salts Chemical class 0.000 claims 5
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 102200085639 rs104886003 Human genes 0.000 claims 4
• 102200085623 rs1057519925 Human genes 0.000 claims 4
• 102200085641 rs121913273 Human genes 0.000 claims 4
• 102200085809 rs867262025 Human genes 0.000 claims 4
• 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 3
• 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 3
• 102220198252 rs1057519936 Human genes 0.000 claims 3
• 102200085789 rs121913279 Human genes 0.000 claims 3
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 208000006218 bradycardia Diseases 0.000 claims 2
• 230000036471 bradycardia Effects 0.000 claims 2
• 201000001421 hyperglycemia Diseases 0.000 claims 2
• 102200085703 rs121913287 Human genes 0.000 claims 2
• 208000003265 stomatitis Diseases 0.000 claims 2
• 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
• 229940126638 Akt inhibitor Drugs 0.000 claims 1
• 239000004114 Ammonium polyphosphate Substances 0.000 claims 1
• 239000004135 Bone phosphate Substances 0.000 claims 1
• 206010012735 Diarrhoea Diseases 0.000 claims 1
• 208000010201 Exanthema Diseases 0.000 claims 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
• 206010019851 Hepatotoxicity Diseases 0.000 claims 1
• 239000012828 PI3K inhibitor Substances 0.000 claims 1
• 108091007960 PI3Ks Proteins 0.000 claims 1
• 206010035664 Pneumonia Diseases 0.000 claims 1
• 206010035742 Pneumonitis Diseases 0.000 claims 1
• 102000015433 Prostaglandin Receptors Human genes 0.000 claims 1
• 108010050183 Prostaglandin Receptors Proteins 0.000 claims 1
• 108091008611 Protein Kinase B Proteins 0.000 claims 1
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
• 230000002411 adverse Effects 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 206010009887 colitis Diseases 0.000 claims 1
• 238000002648 combination therapy Methods 0.000 claims 1
• 201000005884 exanthem Diseases 0.000 claims 1
• 229960002258 fulvestrant Drugs 0.000 claims 1
• 230000007686 hepatotoxicity Effects 0.000 claims 1
• 231100000304 hepatotoxicity Toxicity 0.000 claims 1
• 229960003881 letrozole Drugs 0.000 claims 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
• 229940124302 mTOR inhibitor Drugs 0.000 claims 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
• 229960004390 palbociclib Drugs 0.000 claims 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
• 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
• 206010037844 rash Diseases 0.000 claims 1
• 102220198236 rs1057519927 Human genes 0.000 claims 1
• 102220198245 rs1057519934 Human genes 0.000 claims 1
• 102200085622 rs121913272 Human genes 0.000 claims 1
• 102200085635 rs121913274 Human genes 0.000 claims 1
• 102200085788 rs121913279 Human genes 0.000 claims 1
• 102200085787 rs121913283 Human genes 0.000 claims 1
• 102200085791 rs121913286 Human genes 0.000 claims 1
• 102200085808 rs397517201 Human genes 0.000 claims 1
• 102200085646 rs587777790 Human genes 0.000 claims 1